SOURCE: Bio-Rad Laboratories

March 05, 2007 16:05 ET

Bio-Rad's Recent Appointment of New Board Member Brings the Company Into Compliance With the American Stock Exchange

HERCULES, CA -- (MARKET WIRE) -- March 5, 2007 --Bio-Rad Laboratories, Inc. (AMEX: BIO) (AMEX: BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that after its recent appointment of Louis Drapeau to Bio-Rad's Board of Directors in late February, the American Stock Exchange has confirmed that Bio-Rad is in compliance with AMEX listing rules. Mr. Drapeau will serve on the Board's Audit Committee. He replaces Philip L. Padou who passed away late last year.

Mr. Drapeau will stand for election to the Board along with Bio-Rad's other directors at the Company's Annual Meeting on April 24, 2007.

Mr. Drapeau currently serves as Chief Financial Officer and Senior Vice President of Finance at Nektar Therapeutics. Previously, he has served in several executive positions at BioMarin Pharmaceutical, Inc., and Audit Partner and Managing Partner of Northern California Audit and Business Consulting at Arthur Andersen. Mr. Drapeau currently serves on the Board of Directors of Inflazyme Pharmaceuticals Ltd. where he is the Chair of the Board's Audit Committee.

About Bio-Rad

Bio-Rad Laboratories, Inc. (AMEX: BIO) (AMEX: BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 5,000 people globally and had revenues of $1.3 billion in 2006. For more information, visit www.bio-rad.com.

Various statements made within this press release may constitute "forward-looking statements" for the purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectation.

Contact Information

  • For more information contact:
    Tina Cuccia
    Corporate Communications Manager
    Bio-Rad Laboratories, Inc.
    510-724-7000
    Email Contact